Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products
Published 2 months, 3 weeks ago
Description
In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter a five-year manufacturing agreement, Novo Nordisk announces significant price reductions for its leading GLP-1 therapies, and Astellas enters a billion-dollar global collaboration with Vir Biotechnology to advance PSMA-targeting cancer treatments.